Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Johanna RichterInstitute for Molecular Bioscience, Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0002-2043-0003
Amanda J CorkInstitute for Molecular Bioscience, Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0003-2207-6877
Yvette OngInstitute for Molecular Bioscience, Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0002-4440-5785
Nadia KellerInstitute for Molecular Bioscience, Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, Queensland, Australia.
Andrew J HayesDepartment of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia.ORCID 0000-0001-8038-1656
Mark A SchembriInstitute for Molecular Bioscience, Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0003-4863-9260
Amy V JennisonPublic and Environmental Health, Pathology Queensland, Queensland Health, Coopers Plains, Queensland, Australia.ORCID 0000-0002-5599-7480
Mark R DaviesDepartment of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia.ORCID 0000-0001-6141-5179
Kate Schroder *Institute for Molecular Bioscience, Centre for Inflammation and Disease Research, The University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0001-9261-3805
Mark J Walker *Institute for Molecular Bioscience, Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0001-7423-2769
Stephan Brouwer *Institute for Molecular Bioscience, Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0002-9777-2992
Funding
Identifying the Most Effective Adjuvant(s) for Leading Group A Streptococcal Vaccine Antigens in Preclinical Mouse and Nonhuman Primate ModelsR01AI173689 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Victor Nizet, Mark Joseph Walker · 2023 to 2026
$2.8M
DHAC | National Health and Medical Research Council (NHMRC) 1194130DHAC | National Health and Medical Research Council (NHMRC) 2009677DHAC | National Health and Medical Research Council (NHMRC) 2019767NIAID NIH HHS R01 AI173689
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Characterization of a novel · full record | OpenQuestion